Serum levels of soluble intercellular-1 and vascular cell-1 adhesion molecules in chronic hepatitis C and the influence of interferon-alpha + ribavirin therapy

Rom J Gastroenterol. 2002 Dec;11(4):277-83.

Abstract

In chronic hepatitis C (CHC) intercellular and vascular cell adhesion molecules-1 (ICAM-1 and VCAM-1) are expressed de novo on hepatocytes infected by hepatitis C virus and on endothelial cells from sinusoidal vessels, respectively. The soluble forms of these (sICAM-1 and sVCAM-1) reflect their level of expression in tissue. Serum levels of sICAM-1 and VCAM-1 were measured using ELISA assays in 20 patients with CHC, at baseline and after 6 months of treatment with interferon-a + ribavirin. Significantly higher mean values of both adhesions, comparing to healthy controls, were observed. In all patients the lowest value of sICAM-1 was above highest level of controls. At the beginning of the study the responders and nonresponders to treatment (at 1 year) did not differ from each others concerning sICAM-1/sVCAM-1 concentrations. A significant reduction of sICAM-1 levels was apparent after 6 months of therapy, especially in the group of responders. Just a normalization of sICAM-1 values in all but one of responders, comparing to only 5 of 9 nonresponders has been achieved. By contrast, the mean level of sVCAM-1 did not change significantly with therapy. In conclusion, the normalization of serum sICAM-1 at 6 months of treatment may be useful prognostic parameter of response to the end of the administration period (1 year).

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / pharmacology*
  • Biomarkers / analysis
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / pathology*
  • Humans
  • Intercellular Adhesion Molecule-1 / biosynthesis
  • Intercellular Adhesion Molecule-1 / blood*
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / pharmacology*
  • Male
  • Middle Aged
  • Prognosis
  • Ribavirin / administration & dosage
  • Ribavirin / pharmacology*
  • Treatment Outcome
  • Vascular Cell Adhesion Molecule-1 / biosynthesis
  • Vascular Cell Adhesion Molecule-1 / blood*

Substances

  • Antiviral Agents
  • Biomarkers
  • Interferon-alpha
  • Vascular Cell Adhesion Molecule-1
  • Intercellular Adhesion Molecule-1
  • Ribavirin